Fusion Antibodies Completes £1.2 million Financing Round
Professor Sir John Cadogan, Chairman of Fusion Antibodies said: "This further investment is a welcome and significant measure of support from our existing and new investors, particularly Crescent and Invest Northern Ireland. Their involvement highlights the confidence in Fusion, underlining the potential of our approach to developing novel cancer therapeutics."
The investment will be used to develop the Company's leading programmes through later stage preclinical development, thus strengthening the company's pipeline of therapeutic antibodies. The latest data with the companies leading drug shows great potential in tumour regression.
In addition to the funding round Fusion has been awarded a £400,000 grant towards their research program through the Invest Northern Ireland START programme. START aims to increase the level of industrial level research and development carried out by local businesses and universities.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous